January 2004 in “Data Archiving and Networked Services (DANS)” Finasteride blocks progesterone's effect on brain activity linked to epilepsy.
22 citations
,
February 2008 in “Journal of Neurochemistry” Minoxidil prevents serotonin loss from MDMA by affecting potassium channels and increasing Akt phosphorylation.
13 citations
,
October 2010 in “Seizure” Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
6 citations
,
July 2018 in “Scientific Reports” Methamphetamine affects gene expression in rat whisker follicles, with key genes linked to addiction.
12 citations
,
August 2018 in “Psychiatry research” Estazolam reduces anxiety-like behavior in PTSD by increasing allopregnanolone levels.
April 2012 in “Reactions Weekly” Finasteride may cause more sexual side effects than previously thought.
September 2025 in “Therapies” Finasteride use for hair loss may cause depression and suicidal thoughts, requiring careful monitoring.
January 2013 in “The Journal of Sexual Medicine” The document suggests that finasteride may cause depression and suicidal thoughts, while prostate surgery does not harm sexual health.
2 citations
,
June 2017 in “Psychiatry and clinical psychopharmacology” Stopping the antidepressant agomelatine improved hair loss in a patient.
134 citations
,
August 2012 in “The Journal of Clinical Psychiatry” Former finasteride users with persistent sexual side effects have higher rates of depression and suicidal thoughts.
1 citations
,
January 2013 in “Digital Scholarship - UNLV (University of Nevada Reno)” Targeting neurosteroids may help prevent drug relapse.
May 2025 in “Reactions Weekly” January 2015 in “International Journal of Nanomedicine” Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.
8 citations
,
April 2021 in “Journal of Clinical Investigation” Finasteride reduces opioid use and withdrawal symptoms in animals.
December 2025 in “Journal of Cosmetic Dermatology” Finasteride does not increase the risk of depression or suicide.
August 2018 in “Journal of The American Academy of Dermatology” The conclusion is that finasteride is linked to an increased risk of suicidal thoughts and a higher risk of completed suicide when used for hair loss.
47 citations
,
January 2003 in “American Journal of Clinical Dermatology” Mood stabilizers can cause serious skin reactions; careful monitoring and immediate treatment are crucial.
15 citations
,
March 2007 in “Hormones and Behavior” Finasteride boosts morphine's pain relief, stops tolerance, and reduces withdrawal in rats.
31 citations
,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
The combined treatment of Finasteride and Doxazosin affects prostate tissue by reducing cell growth and altering hormone levels.
1 citations
,
May 2021 in “JAMA Dermatology” Finasteride use may be linked to hair loss, depression, anxiety, and suicidal thoughts.
January 2011 in “Reactions Weekly” St. John's Wort may reduce the effectiveness of finasteride by increasing its breakdown in the body.
69 citations
,
July 2015 in “Pharmacotherapy” Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
32 citations
,
July 2016 in “PubMed” 5-alpha reductase inhibitors are generally safe but can cause sexual side effects and require patient education on risks.
5 citations
,
October 2017 in “Journal of Mind and Medical Sciences” Finasteride treatment should be personalized to individual mental profiles.
Some drugs can reduce male semen quality.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.